SITC Introduces Guidelines for Anti–PD-1 Therapy in HNSCC

October 30, 2019 – Based on strong findings for efficacy and safety, as well as FDA approvals, the Society for Immunotherapy of Cancer (SITC) has issued the first guidelines for the use of immunotherapy agents in patients with recurrent or metastatic (RM) head and neck squamous cell carcinoma (HNSCC). Approvals of checkpoint inhibitors in this setting began in 2016, when nivolumab and pembrolizumab were approved for HNSCC that is refractory to platinum-based … (leggi tutto)